Treatment of myeloma - Are we making progress?

New England Journal of Medicine

Volumn 359, Issue 9, 2008, Pages 964-966

  Durie, Brian G M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

CLINICAL TRIAL; DIZZINESS; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOMA; NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME;

EID: 50449090675     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0805176     Document Type: Editorial

References (16)

1. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
2. San-Miguel J, Harousseau J-L, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008;26:2761-6.
3. Stewart AK. A risk-adapted approach to myeloma therapy. In: Govindan R, ed. ASCO 2008 educational book. Alexandria, VA: American Society of Clinical Oncology, 2008:380-4.
4. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-7.
5. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2007;110:31a. abstract.
6. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
7. Facon T, Mary J, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18.
8. Hulin C, Facon T, Rodon P, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007;110:31a. abstract.
9. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65.
10. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. [Errata, Leukemia 2006;20:2220, 2007;21:1134.]
11. Rajkumar SV, Durie BG. Eliminating the complete response penalty from myeloma response criteria. Blood 2008;111:5759-60.
12. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
13. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood 2008;111:4039-47.
14. Jagannath S, Bensinger B, Vescio R, et al. A phase II study of bortezomib (Velcade), cyclophosphamide (Cytoxan), thalidomide (Thalomid) and dexamethasone as first-line therapy for multiple myeloma. Blood 2007;110:63a. abstract.
15. Richardson P, Jagannath S, Raje N, et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary of a phase 1/2 study. Blood 2007;110:63a. abstract.
16. Durie BGM. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005;6:181-90.